Open AccessExtended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
Author(s) -
Sam Schulman,
Clive Kearon,
Ajay K. Kakkar,
Sebastian Schellong,
Henry Eriksson,
David Baanstra,
Anne Mathilde Kvamme,
Jeffrey Friedman,
Patrick Mismetti,
Samuel Z. Goldhaber
Publication year - 2013
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1113697
Subject(s) - medicine , dabigatran , warfarin , hazard ratio , placebo , confidence interval , anesthesia , randomized controlled trial , surgery , atrial fibrillation , alternative medicine , pathology
Dabigatran, which is administered in a fixed dose and does not require laboratory monitoring, may be suitable for extended treatment of venous thromboembolism.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom